Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Executive Summary
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Cathy Kelly, Managing Editor Bridget Silverman and Editor in Chief Nielsen Hobbs consider the questions about a US Centers for Medicare and Medicaid Services' estimate of upcoming spending on Eisai Co., Ltd. and Biogen, Inc.’s Alzheimer’s treatment Leqembi (lecanemab-irmb) (:28), the new role for former US Food and Drug Administration Principal Deputy Commissioner Janet Woodcock (12:28), and the US Centers for Disease Control and Prevention’s ongoing preparation for new pneumococcal vaccines that are nearing market entry (17:28).
More On These Topics From The Pink Sheet
-
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs
-
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
-
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
This and other podcasts are available on the Pink Sheet podcast page, as well as the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.